AUTHORS
Jeff Sharman, MD, John M. Burke, MD2, Farrukh T Awan, M.D.M.S.,M.B.A.3, Joseph Ye4, José Antonio Garcia Vela, MD5, Darko Antic Sr, MD, PhD6, Argiris Symeonidis, MD, PhD7, Maja Popovic8, Vasiliki Pappa, MD9, Mitul Gandhi, MD10, David Berz, MD11, Ralph Vincent Boccia, MD12, Ludovic Fouillet, MD13, Adolfo De la Fuente Burguera, MD14, Ari Pelcovits15, Shalin Kothari, MD16, Allison Winter, MD17, Michael Wei, MD, PhD18, Robson Lima, MD19, Wendy Sinai, PharmD20, Chen Qian21, Jelena Obradovic, MD22, Jacqueline Hilger-Rolfe23, Jalaja Potluri, MD24, Nilanjan Ghosh25
AFFILIATIONS
1 Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, Oregon, United States
2 Rocky Mountain Cancer Centers, Aurora, Colorado, United States
3 UT Southwestern Medical Center, Dallas, Texas, United States
4 Panacea Oncology, Lakewood, Washington, United States
5 Hospital Universitario de Getafe, Getafe, Spain
6 Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia
7 University of Patras, Patras, Greece
8 Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
9 National and Kapodistrian University of Athens School of Medicine, General University Hospital 'Attikon,', Athens, Greece
10 Virginia Cancer Specialists, Fairfax/Manassas, Virginia, United States
11 Valkyrie Clinical Trials, Los Angeles,, California, United States
12 The Center for Cancer and Blood Disorders, Bethesda and Germantown,, Maryland, United States
13 CHU Saint-Étienne, Saint-Priest-en-Jarez, France
14 MD Anderson Cancer Center Madrid Hospiten, Madrid, Spain
15 Warren Alpert Medical School of Brown University; Brown University Health Cancer Institute, Rhode Island Hospital, Providence, Rhode Island, United States
16 Yale School of Medicine; Yale Cancer Center, Smilow Cancer Hospital, New Haven, Connecticut, United States
17 Cleveland Clinic, Cleveland, Ohio, United States
18 Genentech, South San Francisco/Palo Alto, California, United States
19 AbbVie Inc, North Chicago, Illinois, United States
20 AbbVie Inc, North Chicago, Illinois, United States
21 AbbVie Inc, North Chicago, Illinois, United States
22 AbbVie Inc, North Chicago, Illinois, United States
23 AbbVie Inc, North Chicago, Illinois, United States
24 AbbVie Inc, North Chicago, Illinois, United States
25 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
ABSTRACT
Background and Significance BCL-2 inhibitors (BCL2i) induce apoptosis, increasing the risk of tumor lysis syndrome (TLS). Venetoclax (Ven), a highly selective oral BCL-2 inhibitor, is a standard-of-care option for untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). A treatment approach that includes an agent that helps lower tumor burden (TB), prior to Ven ramp up, mitigates the risk of TLS. A simplified TLS mitigation strategy that preserves safety would reduce logistical and financial burden on patients (pts), clinical practices, and healthcare systems. Here, we present results from the primary analysis of the VENETIAN study (NCT06428019) evaluating different debulking and/or ramp-up strategies to minimize tumor burden and support optimized Ven initiation without compromising safety.
Study Design and Methods VENETIAN is a global, open-label Phase 2 study assessing TLS risk with Ven + debulking agents obinutuzumab (Obi) or acalabrutinib (Acala) in first-line CLL/SLL. First-line adult pts requiring treatment per 2018 iwCLL criteria, with ECOG PS 0–2, and creatinine clearance (CrCl) ≥30 mL/min were randomized 1:1:1:1 to the following arms: Ven + Obi (Arm A) and Ven + Acala (Arm B) per label; Arms C and D (Ven + Acala) explored 6- and 7-week Ven ramp-up periods, respectively. TB was assessed prior to starting treatment (debulking) and prior to Ven ramp-up (post debulking) using low, medium, and high TB based on lymph node size and absolute lymphocyte count (ALC). All pts were to receive TLS prophylaxis per label. The primary endpoint was incidence of treatment-emergent (TE) laboratory TLS or hyperkalemia (>6.0 mmol/L) per Howard criteria (HC) requiring clinical intervention confirmed by independent review committee (IRC) during Ven ramp-up. Pts who initiated Ven as outpatients per label (medium [CrCl ≥80 mL/min] or low tumor TB [any CrCl level] post debulking) were pre-specified as evaluable. Secondary endpoints were IRC-assessed incidence of laboratory TLS or hyperkalemia requiring clinical intervention (ie, managing metabolic abnormalities, interrupting or reducing Ven dose) at each dose level and each laboratory monitoring point, adverse events (AEs) of TLS during ramp-up and percentage of pts with TB reduction from baseline to post debulking.
Results As of March 3, 2026, of the 171 pts randomized, 170 were treated with a debulking agent, and 163 received Ven (Arm A: n=38 [30 evaluable]; Arm B: n=42 [33 evaluable]; Arm C: n=41 [29 evaluable]; and Arm D: n=42 [31 evaluable]); 7 pts discontinued during debulking (withdrawal [n=2] and AE [n=5]). Among pts who received Ven, median age was 68 years (range, 40–87) and 98% had an ECOG PS of 0-1. Post-debulking, median CrCl prior to Ven was 81 mL/min (range, 25–173; ≥80 mL/min: 54%); 49% and 46% had a low and medium TB, respectively. No IRC-assessed TE laboratory or clinical TLS per HC requiring clinical intervention was reported in evaluable pts across all arms regardless of the TB categories. One evaluable pt in Arm A with low TB (CrCl of 35ml/min post debulking) had hyperkalemia (6.3 mmol/L) meeting HC at an unscheduled lab monitoring timepoint on Day 7 of 20 mg dose. One unevaluable pt in Arm C with medium TB (CrCl of 25 ml/min post debulking) reported an adverse event of lab TLS (elevated phosphorous and urate) at the 50 mg 24-hour timepoint. Most common single lab abnormality irrespective of intervention was hyperphosphatemia (19/163). Further, hyperuricemia (3/163) and hyperkalemia (1/163) were reported. Interventions for lab abnormalities included additional hydration, diuretics and/or drug interruptions. No clinical TLS, clinical symptoms or treatment related deaths occurred across any arm or dose in evaluable and unevaluable pts. Reduction in TB category in evaluable pts with medium or high TB at baseline occurred in 20 (67%), 15 (45%), 12 (41%) and 16 (52%) pts in Arms A, B, C and D, respectively.
Conclusion In this study, initiation of Ven post debulking with Obi or Acala was associated with a very low incidence of TLS and hyperkalemia during Ven ramp-up. One event of hyperkalemia occurred at an unscheduled lab timepoint, and one event of lab TLS was reported at the 50 mg 24-hour timepoint (unevaluable pt); both pts had low CrCl, a known risk for TLS. The low rate of TLS (<1%) with label indicated ramp up after debulking supports optimized Ven initiation without compromising safety in pts with previously untreated CLL/SLL.
DISCLOSURES
Jeff Sharman, MD: AbbVie - Honoraria; Lilly - Honoraria; Bristol Myers Squibb - Honoraria; AstraZeneca - Honoraria; Merck - Honoraria; BeOne - Honoraria; Genentech - Consultancy (Includes expert testimony)